Statement/Regulatory AdmissionAflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA15-Nov-2024 / 18:18 CET/CESTDisclosure of an inside information acc. to Article ...

Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA ...

Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration ...

Kodiak Sciences Inc. , today reported business highlights and financial results for the quarter ended September 30, 2024. "In the third quarter we hosted an Investor R&D Day in New York," said Victor ...

Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital, dedicated to the development and ...

KOCHI: 68-year-old Thankamma (name changed) from Ernakulam has been a diabetic patient for 15 years. As she did not manage ...

The Cure are undeniably one of the most distinctive bands to emerge from the creative wave of the 1980s. Formed in the late ’70s amidst the post-punk explosion, their sound has transformed from raw ...

Huw Stephens presents an exclusive session from The Cure, recorded at the BBC Radio Theatre in London and including tracks from their upcoming album Songs of a Lost World. Show more Huw Stephens ...

and by 5 points to 20% in retinal vein occlusion. In terms of new patient share, Vabysmo is capturing about 50% of treatment-naïve patients, up from around 40% in earlier quarters, the company added.

“Finding an inexpensive and patient-friendly biomarker for detection of AD could enable early detection, paving the way for initiation of treatment to prevent or ... the potential to reveal new ...

and as an adjunct therapy for diabetic macular oedema and retinal vein occlusions.” They said they are proud to be the first in Namibia to offer this state-of-the-art treatment, reflecting the ...